Trending...
- UNCLE LEROY'S HOUSE The Next Big Comedy Unites a Powerhouse Team of Black Female Storytellers and Producers - 168
- San Jose Holiday Lights Returns to Downtown San Jose for the 2026 Season - 137
- Mesa West Capital Provides $61.5 Million Loan to Finance Silicon Valley Office Property - 109
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
- As federal immigration enforcement intensifies, California continues connecting families to protections, deepens new efforts to expand legal capacity
- All Long Beach Open Coastal Swimming Areas Temporarily Closed Due to Local Sewage Spill
- Landscaper-Near-Me.com Launches Redesigned Landscaping Homepage
- Vertical Reality Films debuts The Protocol: 25 episodes produced in two weeks for under $1,000
- Queen Hollywood Alicee Enters Next Music Star to Claim Sovereignty & Bring Her Babies Home
Filed Under: Business
0 Comments
Latest on The Californer
- THE DASH CAM: THINKWARE to Showcase Dash Cam Lineup at SEMA 2026
- Federal Court slaps down Trump Administration attack on California democracy for third time this week
- Andy Sehremelis of Parkcrest Construction Highlights Three Decades of Commercial Development
- AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
- Dr. Stout Joins Community Advisory Board
- Steve Weclew is Appointed by STS Capital Partners as Managing Director
- Governor Newsom names new California Labor and Workforce Development Agency Building after Labor and Civil Rights Icon Dolores Huerta
- New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
- California: First Partner Jennifer Siebel Newsom leads final Gender Equity Summit, launches roadmap to advance women's wealth
- Governor Newsom secures innovative approach to major Bay-Delta protections that will restore rivers and strengthen California's water future
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Governor Gavin Newsom announces strike team to support California's preparations for 2028 Olympic and Paralympic Games
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
- City of Long Beach Announces Entertainment Lineup for Día de Los Muertos Celebration
- Warrior Foundation Freedom Station Announces Give-A-Thon to Fly Warriors "Home for the Holidays!"
- Can You Spot the Next Trillion-Dollar Company? Blueshift Launches Global Prediction Challenge
- Save the Date! Long Beach's 72nd Annual Daisy Lane Parade Returns Dec. 12
- No Days Off Reception Introduces Free Business-Name Preview for U.S. Contractors
- Cashback Loans Shares Last Minute Halloween Ideas for California Families
- For National Novel Writing Month: Will this be the year my fascinating Novel finally gets Published?